The latest price target for Cipher Pharmaceuticals (OTCQX:CPHRF) was reported by Stifel on June 1, 2023. The analyst firm set a price target for $4.75 expecting CPHRF to fall to within 12 months (a possible NaN% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Cipher Pharmaceuticals (OTCQX:CPHRF) was provided by Stifel, and Cipher Pharmaceuticals upgraded their speculative buy rating.

The last upgrade for Cipher Pharmaceuticals Inc happened on June 1, 2023 when Stifel raised their price target to $4.75. Stifel previously had a hold for Cipher Pharmaceuticals Inc.

There is no last downgrade for Cipher Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cipher Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cipher Pharmaceuticals was filed on June 1, 2023 so you should expect the next rating to be made available sometime around June 1, 2024.

While ratings are subjective and will change, the latest Cipher Pharmaceuticals (CPHRF) rating was a upgraded with a price target of $0.95 to $4.75. The current price Cipher Pharmaceuticals (CPHRF) is trading at is $undefined, which is out of the analyst’s predicted range.